Page 132 - புதுப்பிக்கப்பட்டது அணிவகுப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the body s immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily. 2 KIRKLAND, QC, March 8, 2021 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has approved KEYTRUDA ® (pembrolizumab), Merck s anti-PD-1 therapy, for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). 3 This approval offers a new first-line treatment option for patients with MSI-H/dMMR metastatic colorectal cancer, said Dr. Ron Burkes, Professor of Medicine, University of Toronto and Medical Oncologist, Mount Sinai Hospital.

United statesAlannah nugentAnna van ackerRon burkesBarryd steinNational cancer instituteMerck coStatement of merck coExchange commissionUniversity of torontoMerck co incCanadian cancer societyCanadian agency for drugsSurveillance research programHealth canadaTechnologies in health